摘要
目的讨论不同分子分型和临床病理特征和青年乳腺癌化疗术后预后的关系。方法回顾性分析2014年4月—2015年5月我院就诊的青年乳腺癌患者并进行化疗术治疗的132例病例资料,根据免疫组化发对其进行分子分型,并观察其分型、临床病理特征和化疗术后预后之间关系。结果(1)luminal A型、luminal B型、人表皮生长因子-2型(HER-2+型)以及三阴型乳腺癌在病理分型和触及肿块至就诊时间方面差异具有统计学意义,统计学显示(χ^(2)=22.728,P=0.007)、(χ^(2)=21.413,P=0.011),在肿瘤直径、病理分级、淋巴结节转移数以及AJCC分期方面差异无统计学意义,统计学显示(χ^(2)=3.908,0.689)、(χ^(2)=0.299,P=0.960)、(χ^(2)=6.065,P=0.733)和(χ^(2)=0.514,P=0.916);(2)luminal A型、luminal B型、人表皮生长因子-2型(HER-2+型)以及三阴型乳腺癌患者在5年无病生存率方面差异无统计学意义,统计学显示(χ^(2)=6.952,P=0.283)。结论青年乳腺癌患者不同分子型分别具有不同的临床病理特征,但是在化疗后5年无病生存率均较好。
Objective To discuss the relationship between different molecular typing,clinicopathological features and prognosis of young breast cancer after chemotherapy.Methods The data of 132 young patients with breast cancer treated with chemotherapy in our hospital from April 2014 to May 2015 were analyzed retrospectively,and the molecular types were classified according to immunohistochemistry.The relationship between the classification,clinicopathological features and prognosis after chemotherapy was observed.Results(1)There were significant differences among luminal A type,luminal B type,human epidermal growth factor-2(HER-2+type)and triple negative breast cancer in pathological classification and time from touching the mass to seeing a doctor.Statistics showed that there were no significant differences in tumor diameter,pathological grade,number of lymph node metastasis and AJCC stage(χ^(2)=22.728,P=0.007)、(χ^(2)=21.143,P=0.011),but not in tumor diameter,pathological grade,number of lymphoid nodule metastasis and AJCC stage,there were significant differences(χ^(2)=3.908,0.689)、(χ^(2)=0.299,P=0.960)、(χ^(2)=6.065,P=0.733)and(χ^(2)=0.514,P=0.916).(2)there was no significant difference in 5-year disease-free survival rate among patients with luminal A,luminal B,human epidermal growth factor-2(HER-2+type)and triple negative breast cancer(χ^(2)=6.952,P=0.283).Conclusion Different molecular types of young breast cancer patients have different clinicopathological characteristics,but the 5-year disease-free survival rate is better after chemotherapy.
作者
陈昌明
CHEN Changming(Pathology Department,Sanming First Hospital,Sanming Fujian 365000,China)
出处
《中国卫生标准管理》
2021年第18期73-75,共3页
China Health Standard Management
关键词
分子分型
临床病理特征
青年乳腺癌
化疗
预后
生存率
molecular typing
clinicopathological features
young breast cancer
chemotherapy
prognosis
survival rate
